Genzyme Strengthens Oncology And MS Portfolios With Bayer Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The complicated deal bolsters Genzyme’s developing oncology franchise and provides a potential MS blockbuster without requiring an up-front payment.
You may also be interested in...
Oral Fludarabine Gives Antisoma Breathing Room
Antisoma’s deal with Sanofi-Aventis provides two years of cash, allowing the biotech to focus on its pipeline.
Oral Fludarabine Gives Antisoma Breathing Room
Antisoma’s deal with Sanofi-Aventis provides two years of cash, allowing the biotech to focus on its pipeline.
Genzyme Plays Up Emerging Blood Cancer Business In R&D Review
Genzyme has set its sights on emerging as a hematologic cancers specialist – a strategy made possible by a deal made in March, when it gained full rights to Campath from partner Bayer and brought in two additional blood cancer therapies.